Company Encyclopedia
View More
name
iShares Core S&P US Value
IUSV.US
News
View More

2 Growth Stocks That Have Beaten the Market in Just 2 of the Past 5 Years

Netflix and Amazon have underperformed the market in recent years but show strong growth potential. Netflix's stock rose 80% since 2020, despite subscriber losses, and is expected to grow earnings by 24% annually. Amazon's stock trailed the S&P 500, yet its cloud computing and non-retail services drive profitability. Both companies are poised for long-term market-beating returns.

Motley Fool·
US
AMZN
+2.48%
US
NFLX
-0.83%
US
AMZU
+4.95%
Motley Fool·
US
AMZN
+2.48%
US
NFLX
-0.83%
US
AMZU
+4.95%

FCG Investment Co Raises Stock Position in Nucor Corporation $NUE

FCG Investment Co increased its stake in Nucor Corporation by 284.8% in Q3, owning 9,921 shares valued at $1,344,000. Other major investors like Berkshire Hathaway and Norges Bank also acquired significant positions in Nucor. The stock opened at $157.69, with a market cap of $36.09 billion. Analysts have given Nucor a "Moderate Buy" rating, with a target price of $172.60. Nucor announced a quarterly dividend increase to $0.56 per share.

Market Beat·
US
BRK.B
-0.17%
US
BRK.A
-0.06%
US
NUE
-1.78%
Market Beat·
US
BRK.B
-0.17%
US
BRK.A
-0.06%
US
NUE
-1.78%

J&J receives FDA approval for lung cancer therapy

Johnson & Johnson (J&J) has received US FDA approval for Rybrevant Faspro, a subcutaneously administered therapy for treating patients with EGFR-mutated non-small cell lung cancer (NSCLC). The approval is based on the Phase III PALOMA-3 study, which showed improved overall survival and progression-free survival compared to intravenous delivery. The SC formulation reduces administration time to five minutes, enhancing patient convenience. The safety profile is consistent with IV administration. This approval provides greater access to treatment for EGFR+ NSCLC patients.

Pharmaceutical Technology·
US
JNJ
-0.96%
Pharmaceutical Technology·
US
JNJ
-0.96%

Update: Market Chatter: Banks Win Bid to Block $3.2 Billion Foreign Exchange Rigging Lawsuit in UK

Major banks, including JPMorgan, UBS, and Citigroup, successfully blocked a $3.2 billion lawsuit in the UK over alleged foreign exchange rigging. The lawsuit, led by Phillip Evans on behalf of asset managers and financial institutions, was based on European Commission findings of collusion in the forex market. The court's decision provides guidance on managing opt-out applications. JPMorgan and Barclays declined to comment, while others did not respond.

fidelity·
US
JPM
-0.63%
US
C
+1.23%
fidelity·
US
JPM
-0.63%
US
C
+1.23%

Direxion Daily BRKB Bull 2X Shares (NASDAQ:BRKU) Stock Price Down 0.2% - Time to Sell?

Direxion Daily BRKB Bull 2X Shares (NASDAQ:BRKU) saw a 0.2% decline in stock price, trading at $25.29 with a 32% decrease in trading volume. The ETF, which offers 2x leveraged exposure to Berkshire Hathaway stock, recently increased its quarterly dividend to $0.1543. Optiver Holding B.V. acquired a new stake in the fund. Despite a Hold rating, analysts suggest other stocks as better investments. The fund's 50-day and 200-day moving averages are $24.90 and $24.88, respectively.

Market Beat·
US
BRK.A
-0.06%
US
BRK.B
-0.17%
Market Beat·
US
BRK.A
-0.06%
US
BRK.B
-0.17%
© 2025 Longbridge｜Disclaimer